February 1, 1989Journal of Internal Medicine
Haemorrhagic and thromboembolic complications in patients with atrial fibrillation on anticoagulant prophylaxis
Population
213 patients with atrial fibrillation receiving anticoagulant treatment, categorized into three groups…
Comparison
Anticoagulant (AC) treatment vs Comparison between patient subgroups
Design
Cohort
Follow-up
818 patient-years total
Authors
Discussion
Loading...
Member takes
Implication
May identify AF patients on anticoagulation at elevated bleeding risk; observational data leaves open need for prospective validation.
Structured PICO
P
Population
213 patients with atrial fibrillation (AF) receiving anticoagulant treatment, categorized into three groups: mitral valve disease (MVD; n=34), without MVD (n=102), and previous thromboembolism (TE; n=77).
I
Intervention
Anticoagulant (AC) treatment
C
Comparator
Comparison between patient subgroups (MVD vs. non-MVD vs. previous TE)
O
Outcome
Clinically relevant haemorrhagic and thromboembolic events (major peripheral haemorrhages, cerebrovascular events, and peripheral arterial thromboembolism)safety
In patients with atrial fibrillation on anticoagulant therapy, major hemorrhagic complications are frequent and most likely to occur in those with a history of thromboembolism or unstable anticoagulation control.
Cite This Study
Lundström et al. (1989) studied this question.